financetom
Business
financetom
/
Business
/
Marvell sinks as weak data center outlook stokes AI chip worries
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Marvell sinks as weak data center outlook stokes AI chip worries
Aug 29, 2025 1:37 AM

(Reuters) -Shares of Marvell Technology slumped 11.3% in premarket trading on Friday as the chipmaker's data center demand outlook fell short of lofty expectations after investors bet big on custom chips that power AI workloads for cloud giants such as Microsoft and Amazon.

Investor expectations for AI-focused chipmakers have been elevated, but recent results have shown signs of a cooling market. Nvidia's latest earnings beat forecasts, but its data center growth slowed and shares fell post-report. Peer Broadcom has yet to report.

Marvell's reliance on so-called custom application-specific integrated circuits exposes it to customer inventory-led swings in demand.

CEO Matthew Murphy said on a post-earnings call on Thursday that data center revenue in the third quarter will be flat on a sequential basis, but did not elaborate on the source of the weakness.

Murphy said "lumpiness" was normal when large cloud compute providers build out infrastructure.

"We aren't surprised at lumpiness, but we are surprised that the ASIC (chips business) full year (revenue) continues to fall," Morgan Stanley analysts said.

A recent media report said that Microsoft had delayed its in-house AI chip rollout to 2028 or later, potentially impacting Marvell's pipeline, as it supplies key components for those designs.

Amazon Web Services, another major customer for Marvell, has been ceding ground to faster-growing rivals, with Microsoft's Azure and Alphabet's Google Cloud outpacing AWS in recent quarters.

Kinngai Chan, an analyst at Summit Insights, said that Marvell lacks scale relative to bigger peers and that large customers pursuing a multivendor sourcing strategy could weigh on its margins.

Marvell reported second-quarter revenue of $2.01 billion, matching Wall Street expectations, but its third-quarter forecast of $2.06 billion, plus or minus 5%, came in below analysts' average estimate of $2.11 billion.

It has a 12-month forward price-to-earnings ratio of 23.95, compared with Broadcom's 39.03, according to data compiled by LSEG, a gap that reflects investor caution around its growth prospects.

(Reporting by Rashika Singh in Bengaluru; Editing by Mrigank Dhaniwala)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved